Home » Stocks » PHVS

Pharvaris, N.V (PHVS)

Stock Price: $28.75 USD -4.86 (-14.46%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 951.06M
Revenue (ttm) n/a
Net Income (ttm) -22.10M
Shares Out 31.84M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $28.75
Previous Close $33.61
Change ($) -4.86
Change (%) -14.46%
Day's Open 34.06
Day's Range 28.14 - 34.62
Day's Volume 139,702
52-Week Range 23.06 - 42.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists...

GlobeNewsWire - 2 weeks ago

Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volun...

GlobeNewsWire - 3 weeks ago

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercia...

GlobeNewswire - 1 month ago

ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...

Pipeline Review - 1 month ago

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.

NASDAQ - 1 month ago

Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

SEC - 1 month ago

Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.

About PHVS

Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Berndt Modig
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
PHVS
Full Company Profile

Financial Performance

Financial numbers in millions Euro.
Financial Statements